Genprex, Inc. Files 8-K on Delisting Concerns
Ticker: GNPX · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1595248
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: GNPX
TL;DR
Genprex 8-K filed: Delisting concerns raised, potential stock impact.
AI Summary
Genprex, Inc. filed an 8-K on September 26, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Austin, Texas.
Why It Matters
This filing indicates potential issues with Genprex, Inc.'s continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Numbers
- 001-38244 — SEC File Number (Identifies the company's filing history with the SEC.)
- 90-0772347 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- 0001437749-24-030088 (filing_id) — Accession Number
- September 26, 2024 (date) — Date of report
- Austin, TX (location) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific listing rule or standard has Genprex, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Genprex, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What are the potential consequences of this delisting notice for Genprex, Inc.?
A delisting notice can lead to the company's securities being removed from the exchange, potentially causing a significant drop in stock price and reduced liquidity.
When was this 8-K form filed with the SEC?
This Form 8-K was filed with the SEC on September 26, 2024.
Where are Genprex, Inc.'s principal executive offices located?
Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the SIC code for Genprex, Inc.?
The Standard Industrial Classification (SIC) code for Genprex, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 861 words · 3 min read · ~3 pages · Grade level 13.2 · Accepted 2024-09-26 17:15:33
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on The
Filing Documents
- gnpx20240920_8k.htm (8-K) — 30KB
- 0001437749-24-030088.txt ( ) — 163KB
- gnpx-20240926.xsd (EX-101.SCH) — 3KB
- gnpx-20240926_def.xml (EX-101.DEF) — 12KB
- gnpx-20240926_lab.xml (EX-101.LAB) — 15KB
- gnpx-20240926_pre.xml (EX-101.PRE) — 12KB
- gnpx20240920_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 26, 2024, Genprex, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, based upon the closing bid price of the Company's common stock, par value $0.001 per share ("Common Stock"), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Nasdaq notification has no immediate effect on the listing or trading of the Company's Common Stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2025 (the "Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time during this 180-day period, the closing bid price of the Company's Common Stock is at least $1.00 for a minimum of 10 consecutive business days, subject to the Staff's discretion to extend such 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H), the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed. If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify for such additional compliance period, the Company would have to (i) meet the continued listing requirement for market value of publicly held shares and all other initial listing standards of The Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and (ii) provide writ
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: September 26, 2024 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)